Is MoonLake Immunotherapeutics (MLTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.8% / 30% | 30.3% / 30% | 0.4% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 5.8% / 33% | 30.3% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| MSCI | 17.8% / 33% | 92.8% / 33% | 1.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 5.8% / 33% | 30.3% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| FTSE | 17.8% / 33% | 92.8% / 33% | 1.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -60.8% | |
| Return on Assets (ROA) | -33.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$196M |
| Free Cash Flow | -$196M |
| Total Debt | $76M |
| Debt-to-Equity | 24.9 |
| Current Ratio | 9.3 |
| Total Assets | $424M |
Price & Trading
| Last Close | $17.75 |
| 50-Day MA | $16.88 |
| 200-Day MA | $28.25 |
| Avg Volume | 2.0M |
| Beta | 1.2 |
|
52-Week Range
$5.95
| |
About MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MoonLake Immunotherapeutics (MLTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MoonLake Immunotherapeutics is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MoonLake Immunotherapeutics's debt ratio?
MoonLake Immunotherapeutics's debt ratio is 5.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 17.8%.
What are MoonLake Immunotherapeutics's key financial metrics?
MoonLake Immunotherapeutics has a market capitalization of $1.2B. Return on equity stands at -60.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.